

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/796,522
				Filing Date	March 9, 2004
				First Named Inventor	Joseph Poduslo
				Art Unit	1649
				Examiner Name	Olga N. Chernyshev
Sheet	1	of	1	Attorney Docket Number	01017/30016A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO 95/11311	04-27-1995	Duke University Strittmatter, et al.		
	B2	WO 99/27944	06-10-1999	Neuralab Limited, et al.		
	B3	WO 02/42462	05-30-2002	Praecis Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bickel et al., Development and <i>in vitro</i> characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease, Bioconj. Chem., 5:119-125, 1994.	
	C2	European Search Report (Supplementary, Partial), EP 02761522.8, European Patent Office, 29 June, 2007.	
	C3	Poduslo et al., Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier, Neuroreport, 12(15):3197-3200, 2001.	
	C4	Wu et al., Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>in vivo</i> with a monoclonal antibody to human insulin receptor, J. Clin. Invest., 100(7):1804-1812, 1997.	
	C5	Zlokovic et al., Glycoprotein 330-megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-cerebrospinal fluid barriers, Proceedings of the National Academy of Sciences of USA, 93(9):4229-4234, 1996.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--